
-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p
On 6ix: 6ix.com/news/newamsterdam-pharma-announces-positive-topline-data-pivotal-phase-3-broadway-clinical

-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p
NewAmsterdam Pharma Company N.V. on 6ix
Follow NewAmsterdam Pharma into a list and get an email when it puts out news.
Follow NewAmsterdam Pharma